Maxygen, Inc. (MAXY)

Following ZZLangerhans. This biotech company is trading for cash value. Thus, more upside than downside.

I'm basing this pick on simple arithmetic. The company has a market cap of 195M and shareholder equity of 193M. That leaves an enterprise value of 2M for the 83% ownership of the Perseid LLC joint venture with Astellas and Maxy-G34. Argue what you will about Perseid and Maxy-G34. The market is currently valuing them at nil. An Astellas buyout of Perseid or a partnership for Maxy-G34 should send this back over 7. And what's going to drive them down below cash?

I think that this is one of the few stocks which can't go down much from here. Because - They have $5 in cash, Have stripped away essentially all their expenses by transferring their people to a joint venture and have curtailed their R&D. So what you end up with a small stream of revenue and interest in a number of technologies through JV's which the market currently values at six bits, Not a bad deal when you look at the terms of their latest JV and see that their partner in the JV, which along with Maxy kicked in $10M in cash, valued Maxy's techology at a about a $1 share based on the split. They also have other tecnologies where fees are possible and losses are not, Expect these guys to throw off a $4-$4.50 cash dividend as they don't appear to have any use for the cash now that they have restructured, I own MAXY in real life

MAXY is great value under $6. $220 market value with $180 million of cash, a joint venture with Astellas, MAXY G34, a potential $30 million milestone from Bayer plus 22% ownership in Codexis. In addition they have their Molecular Breeding technology and a grant funded vaccine program.. Russell really delivered value to shareholders before he left. I shall miss his fantastic australian accent.

following anticitrade.com (currently #2 pick)

This stock is a rare bird. It's a biotech company with a real product and real earnings. They have no long-term debt and a lot of cash. The P/E under 4. Insiders own about a quarter of the company. They have a discipliined growth strategy, using joint ventures with larger,, better-capitalized partners in order to share costs and risks.

Maxygen Inc. (bio technology) has been an underperforming stock since it collapsed during the "tech" collapse. There has always been something in the "pipeline" that gives a false sense of hope that they are almost there and will turn themselves around, but. . .year after year it's the same thing. If your into gambling, this is your stock. If your into investing, stay away.

By the way, their CEO just resigned on July 14, 2009 when they released their qrtly 8-K.

mechanical value screen, no research

outperform. company is HIGH in cash. not terribly overvalued, and is likely to kill S&P 500 where it is at today's levels.
additionally these companies are not within the financials nor energy sectors.

Their pipeline is attracting more partners

Maxygen is a development stage biotech whose existence on the Magic Formula screen is due to a one time, non-recurring cash payment. The stock is extremely speculative and should be avoided.

http://www.magicdiligence.com/articles/magic-formula-stock-to-avoid-maxygen-MAXY

overbought STO

Maxygen Inc. or MAXY is a biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. One of those conditions is the reason that Bayer Inc. is willing to give Maxygen $90Million up-front and another $30Million for the new drug Recombinate which will be used in the treatment of hemophilia. Bayer is currently in control of two other drugs to treat hemophilia The three drugs combined will give Bayer the chance to start drug trials as early as September. Hold on to your seatbelts gang! This stock will rise so fast you'll get nose bleeds..

A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.

yea going down

Momentum play with pull back on a bad dow day

Maxygen Inc a biotechnology company engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions. Its products include Maxy Alpha, Maxy G34, Maxy Factor VII, Maxy Gamma. The company has strategic alliance with Roche, InterMune and Nectar Therapeutics. For 2006, the total revenues increased by 92% to $25 million from $13 million in 2005.

There are more than 1500 players in the biotech industry and this industry is experiencing a sea change with the evolution of partnerships and collaborations among leading companies for development of innovative products.

Roche has initiated a Phase Ia clinical trial in New Zealand to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of Maxy-alpha, a next-generation interferon alpha for the treatment of hepatitis C virus infection. Maxygen expects to receive a $2 million dollar milestone payment for the commencement of the Phase Ia trial. Worldwide sales of drugs for the treatment of hepatitis C virus infections were approximately $2.75 billion in 2005. Moreover, Sales of drugs to treat hepatitis C virus infections are expected to grow due to improved market penetration through improvements in therapies, increased awareness and improved diagnosis rates.

Also the company expects to receive $17.8 million as a result of acquisition of Avidia Inc by Amgen Inc. Avidia was spun out of Maxygen in 2003. Further the company expects to begin the first phase II clinical trial of Maxy G34 in first half of 2007. With new initiatives planned, the shares of Maxygen offer a good opportunity for investors.

Maxygen is one of the few remaining biotechs from the